Onco-Innovations Secures Up to CAD$280,000 in Loans for Working Capital and R&D

July 15, 2026 — Leads & Copy — Onco-Innovations Limited (CBOE: ONCO) has secured up to CAD$280,000 in loan agreements to support its operations and research initiatives. The funding comprises three separate loan agreements, aimed at bolstering the company's working capital and specific research and development activities.

Two of the loan agreements, collectively referred to as the Shareholder Loans, are with arm's length shareholders. These loans provide the company with access to principal amounts of up to CAD$20,000 and CAD$60,000, respectively. The Shareholder Loans carry an annual interest rate of 15%, calculated monthly, and are repayable on demand. Prepayment of these loans is permitted at any time without penalty, with any prepayments first applied to accrued interest and then to the principal amount.

The third loan agreement is with Dr. Islam Mohamed, the Chief Medical Officer of Onco-Innovations, for CAD$200,000. This loan, termed the Other Loan, accrues interest at a rate of 1% per month, calculated monthly. Repayment is structured in two equal tranches of CAD$100,000, with the first due by September 13, 2026, and the second by November 13, 2026. Early repayment on demand or acceleration upon an event of default is also stipulated. Overdue amounts will incur an additional 2% per month, resulting in a default interest rate of 3% per month. While the Other Loan can be prepaid in whole or in part with written notice, a prepayment fee of 2% of the prepaid amount, plus all interest that would have accrued until the maturity date, will apply.

Proceeds from the Shareholder Loans are designated for general working capital purposes. In contrast, the funds from the Other Loan are restricted for use with specific third-party research and development vendors as outlined in the loan agreement.

Due to Dr. Mohamed's position as Chief Medical Officer, the Other Loan is classified as a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions. Onco-Innovations intends to utilize exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101, specifically sections 5.5(a) and 5.7(1)(a). This reliance is based on the fair market value of the Other Loan not exceeding 25% of the Company's market capitalization, as calculated in accordance with MI 61-101.

Onco-Innovations Limited is a Canadian company focused on cancer research and treatment within the oncology field. The company's mission involves the prevention and treatment of cancer through innovative research and solutions. Onco-Innovations holds an exclusive worldwide license for patented technology targeting solid tumors.

Source: Onco-Innovations Limited